https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-12-01 / Leuk. Lymphoma 2003 Dec;44(12):2031-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-12-01 / Leuk. Lymphoma 2003 Dec;44(12):2031-82003-12-01 00:00:002019-02-15 08:51:25Dendritic cell-based immunotherapy in multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-12-01 / Curr. Opin. Mol. Ther. 2003 Dec;5(6):618-24
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-12-01 / Curr. Opin. Mol. Ther. 2003 Dec;5(6):618-242003-12-01 00:00:002019-02-15 09:22:25Overview of phase I studies of intravenous administration of PV701, an oncolytic virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-12-01 / Hum. Cell 2003 Dec;16(4):175-82
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-12-01 / Hum. Cell 2003 Dec;16(4):175-822003-12-01 00:00:002019-02-15 08:46:08Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-12-01 / Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2003 Dec;17(4):365-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-12-01 / Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2003 Dec;17(4):365-82003-12-01 00:00:002019-02-15 08:37:48[Antiviral effect of human CTLs activated by HBsAg stimulated dendritic cells in vitro]
